On Dec. 22, 2020, Resverlogix announced published findings in the Proceedings of the National Academy of Sciences (PNAS), that further supported other 2020 publications and provides new evidence for the therapeutic potential of BET inhibitors in the treatment of COVID-19.

The publication also acknowledged Resverlogix and the Companyﾒs plans to confirm the hypothesis with a clinical trial utilizing its advanced BET inhibition technology.